Lab
Nobility Health, INC.
Nobility Health, INC. was paid $4.16M by Medicaid between Jan 2021 and Dec 2024, across 34 billing codes. Its largest line is 87426, Infectious agent antigen detection, SARS-CoV-2 (COVID-19) — 31% of everything it billed.
33Billing provider infoNOBILITY HEALTH, INC.
GLENDALE, CA 91203
GLENDALE, CA 91203
33aNPI1659969376assigned 01/07/2021
33bProvider typeClinical Medical Laboratory
28Total paid$4.16M
24GClaims144,685
24DCodes billed34
24AFirst – last monthJan 2021 – Dec 2024
Compared with peers
Next to other Clinical Medical Laboratory providers in California
Rank by total paid#115 of 561
Median peer was paid$222K
This provider vs. median19×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2021 | 19,968 | $480K | |
| 2022 | 85,979 | $2.37M | |
| 2023 | 27,220 | $885K | |
| 2024incomplete | 11,518 | $425K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 31% | 41,470 | 24,038 | $1.28M |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 20% | 13,812 | 7,831 | $838K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 13% | 36,629 | 20,760 | $557K |
| G2024 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]) from an individual in a snf or by a laboratory on behalf of a hha, any specimen source | 7.7% | 14,605 | 7,660 | $319K |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | 5.7% | 9,216 | 6,524 | $237K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 4.6% | 4,631 | 3,202 | $193K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | 3.0% | 1,092 | 961 | $125K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | 2.8% | 856 | 796 | $117K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 2.6% | 7,363 | 4,597 | $108K |
| 86328 | 2.0% | 2,069 | 1,908 | $82K | |
| 80504 | 1.3% | 2,036 | 1,506 | $53K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1.0% | 1,522 | 903 | $43K |
22 more codes
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | <1% | 392 | $37K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 480 | $25K |
| 87631 | <1% | 807 | $24K | |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 68 | $20K |
| 87640 | <1% | 746 | $12K | |
| 87486 | <1% | 752 | $12K | |
| 87581 | <1% | 740 | $12K | |
| 86481 | <1% | 252 | $10K | |
| 86803 | <1% | 940 | $9K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 181 | $7K |
| 86780 | <1% | 793 | $7K | |
| 86702 | <1% | 701 | $6K | |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 54 | $6K |
| 87493 | <1% | 354 | $6K | |
| 86701 | <1% | 749 | $4K | |
| 86769 | <1% | 103 | $4K | |
| 86684 | <1% | 403 | $3K | |
| 80503 | <1% | 185 | $2K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 642 | $230.89 |
| 86793 | <1% | 14 | $187.24 | |
| 86632 | <1% | 14 | $90.84 | |
| 86631 | <1% | 14 | $84.60 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialMORADI, SILVA (CEO)
| Provider | Location | Paid |
|---|---|---|
| Avalon Surgery and Robotic Center, LLC | Glendale, CA | $741.93 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.